Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics (NasdaqCM:DNTH) reported Q2 2026 results with a wider net loss of $50.22 million and basic loss per share of $0.90, plus a $91.05 million net loss over six months. The company also introduced DNTH312, a bifunctional fusion protein targeting aC1s and BAFF/APRIL, and cited upcoming clinical catalysts including CAPTIVATE CIDP and EMERGE gMG.
Garcia Marino (CEO AND PRESIDENT) sold 166,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $108.11 ($107.49–$110.76, $17.95M total) across 7 trades on 2026-08-07 under a Rule 10b5-1 trading plan.
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best
Over the past 7 days, alphai's AI scored 2 news stories mentioning DNTH (Dianthus Therapeutics, Inc. /DE/). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent DNTH coverage spans insider activity, technology and earnings.
In the last 30 days, DNTH insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($21.1M). The most active reporter was Garcia Marino, CEO AND PRESIDENT, with 7 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
DNTH312 launch reframes DNTH as a longer-dated autoimmune pipeline story, but near-term valuation still hinges on CAPTIVATE CIDP and EMERGE gMG trial readouts.
Insider selling is disclosed as part of a pre-arranged 10b5-1 plan, which can reduce signaling risk but still may affect near-term sentiment.
Clinical readouts and FDA-agreed protocol changes for claseprubart, alongside cash runway into 2030, are likely to re-rate near-term probability-weighted outcomes.
This is an insider sale disclosure, not a fundamental company update, but it can affect near-term sentiment and positioning.
Inducement option grants add modest dilution/overhang risk but are typically not a fundamental catalyst; the key tradable element is the disclosed strike price and grant size.
alphai scores every news story that mentions DNTH with an AI model for sentiment and relevance, and aggregates insider trades from Dianthus Therapeutics, Inc. /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Dianthus Therapeutics (NasdaqCM:DNTH) reported Q2 2026 results with a wider net loss of $50.22 million and basic loss per share of $0.90, plus a $91.05 million net loss over six months. The company also introduced DNTH312, a bifunctional fusion protein targeting aC1s and BAFF/APRIL, and cited upcoming clinical catalysts including CAPTIVATE CIDP and EMERGE gMG.
6 min readGarcia Marino (CEO AND PRESIDENT) sold 166,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $108.11 ($107.49–$110.76, $17.95M total) across 7 trades on 2026-08-07 under a Rule 10b5-1 trading plan.
2 min readDianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best
7 min readSavitz Ryan (EVP, CFO & CBO) sold 31,249 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $101.03 ($100.22–$101.97, $3.16M total) across 3 trades on 2026-07-09 under a Rule 10b5-1 trading plan.
2 min readDianthus Therapeutics (Nasdaq: DNTH) said it granted inducement equity awards on July 1, 2026 to five newly hired non-executive employees. The grants are non-qualified stock options for 58,000 shares, with a 10-year term and $90.21 exercise price; 25% vest after one year and the rest monthly over 36 months, per Nasdaq Rule 5635(c)(4).
2 min readDianthus Therapeutics (Nasdaq: DNTH) said it initiated the Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis (AChR+). The global, randomized, placebo-controlled study enrolls ~195 patients; claseprubart 300mg/2mL is dosed Q2W or Q4W vs placebo. Top-line results are expected in 2H’28.
4 min readVeness Adam M (SVP, General Counsel and Sec.) sold 30,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $80.80 ($80.34–$81.38, $2.42M total) across 2 trades on 2026-06-17 under a Rule 10b5-1 trading plan.
2 min readRandhawa Simrat (EVP, Head of R&D) sold 4,159 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at $91.37 ($0.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readRandhawa Simrat (EVP, Head of R&D) sold 16,943 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at $90.72 ($1.54M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readRandhawa Simrat (EVP, Head of R&D) sold 5,428 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at $89.72 ($0.49M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
1 min read
